And that's why Merck could credibly become the next big weight-loss stock. Before you rush to go buy shares of Merck, ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

The weight-loss biotech Viking Therapeutics (NASDAQ: VKTX) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...

Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

Merck (MRK) announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific antibody, ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

An FDA approval of Merck’s drug clesrovimab by June would give physicians another option for protecting newborns from ...

Jefferies analyst Akash Tewari has maintained their bullish stance on MRK stock, giving a Buy rating on December 18.Pick the best stocks and ...